Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Other Non-Current Liabilities: 2016-2023

Historic Other Non-Current Liabilities for Cytokinetics (CYTK) over the last 7 years, with Dec 2023 value amounting to $186,000.

  • Cytokinetics' Other Non-Current Liabilities was N/A to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year change of. This contributed to the annual value of $186,000 for FY2023, which is 82.18% down from last year.
  • As of FY2023, Cytokinetics' Other Non-Current Liabilities stood at $186,000, which was down 82.18% from $1.0 million recorded in FY2022.
  • Over the past 5 years, Cytokinetics' Other Non-Current Liabilities peaked at $143.3 million during FY2019, and registered a low of $186,000 during FY2023.
  • In the last 3 years, Cytokinetics' Other Non-Current Liabilities had a median value of $1.0 million in 2022 and averaged $1.9 million.
  • As far as peak fluctuations go, Cytokinetics' Other Non-Current Liabilities rose by 16.99% in 2019, and later tumbled by 82.18% in 2023.
  • Yearly analysis of 4 years shows Cytokinetics' Other Non-Current Liabilities stood at $143.3 million in 2019, then reached $4.5 million in 2021, then tumbled by 76.58% to $1.0 million in 2022, then plummeted by 82.18% to $186,000 in 2023.